Health Promotion Research Center, Zahedan University of Medical Science, Zahedan, Iran.
Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.
Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):37-44. doi: 10.1080/14737167.2021.1941881. Epub 2021 Jul 2.
Chronic heart failure (CHF) is a clinical status and a progressive health disorder extremely related to increased morbidity and mortality worldwide. Accordingly, this study aimed to assess systematic review of literature on cost-effectiveness done in patients with heart failure receiving Ivabradine plus standard treatment compared with standard treatment alone.
This study is a systematic review in which all published articles related to the study topic were assessed in time range of 2014-2020. In order to find articles, internet search in foreign databases of PubMed, Embase, ISI/Web of Science (WoS), SCOPUS, Global Health databases, through keywords related to the objective was performed. Six articles out of 1524 article related to final topic were assessed. In addition, quality of studies was evaluated using CHEERS checklist. In six countries investigated (Iran, Thailand, Australia, United States of America, United Kingdom, and Greece), willingness-to-pay (WTP) thresholds higher cost per QALY, and highest ICER for Ivabradine was in USA (55,600 $/QALY) and the lowest was in Thailand (10,616$/QALY). Most items of CHEERS were estimated in the studies and studies had good quality.
Regarding our investigation, ivabradine combined with standard care was more cost-effective than standard care alone in most of the evaluated studies, although the cost of this intervention was higher than its effectiveness. However, the threshold chosen by each country can have a significant impact on these results. And to have a more accurate result, it is required to pay more attention to the income level in different countries.
慢性心力衰竭（CHF）是一种临床状态，是一种与全球发病率和死亡率增加密切相关的进行性健康障碍。因此，本研究旨在评估接受伊伐布雷定联合标准治疗与单独标准治疗相比的心力衰竭患者的成本效益的文献系统评价。
本研究为系统评价，评估了 2014 年至 2020 年期间与研究主题相关的所有已发表文章。为了找到文章，通过与目标相关的关键字，在国外数据库 PubMed、Embase、ISI/Web of Science（WoS）、SCOPUS、全球健康数据库中进行了互联网搜索。从 1524 篇与最终主题相关的文章中，评估了 6 篇文章。此外，使用 CHEERS 清单评估了研究的质量。在所调查的六个国家（伊朗、泰国、澳大利亚、美国、英国和希腊）中，每个质量调整生命年（QALY）的意愿支付（WTP）阈值更高，伊伐布雷定的最高增量成本效益比（ICER）为美国（55,600 美元/QALY），最低为泰国（10,616 美元/QALY）。在研究中估计了 CHEERS 的大多数项目，并且研究具有良好的质量。
根据我们的调查，伊伐布雷定联合标准治疗比单独标准治疗更具成本效益，尽管这种干预的成本高于其疗效。然而，每个国家选择的阈值会对这些结果产生重大影响。为了获得更准确的结果，需要更加关注不同国家的收入水平。
